Omada Health, Inc. (OMDA) closed the last trading session at $14.53, gaining 28.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $23.18 indicates a 59.5% upside potential.The mean estimate comprises 11 short-term price targets with a standard deviation of $4.62. While the lowest estimate of $17.00 indicates a 17% increase from the current price level, the most optimistic analyst ...

Membership and Engagement - As of December 31, 2025, the company had over 886,000 total members enrolled in its programs and supported nearly two million members since launch [28]. - More than 55% of members in month 12 and over 50% in month 24 of the cardiometabolic programs engaged with the platform at least once during the respective month [28]. - Over 150,000 members across programs have used GLP-1 therapies as of December 31, 2025, demonstrating the company's expertise in supporting members on these treatments [36]. - Omada's customer retention rate averages over 90% over three years, with a customer satisfaction rate of over 90% for program implementation and customer success [64]. - Members on GLP-1s for 12 months lost an average of 16.3% of their baseline weight, compared to 11.9% in other real-world evidence [60]. - 63.2% of members who discontinued GLP-1 therapies for at least 12 months maintained or continued to lose weight at 12 months [60]. - The company must maintain high levels of member engagement and satisfaction to ensure the success of its health management programs [157]. Program Development and Innovation - The company launched its first program focused on diabetes prevention in 2012 and has since expanded to include programs for diabetes management, hypertension, and high cholesterol [30]. - The first commercial launch of the Omada for Cholesterol program is expected in 2026, with a broad launch planned for 2027 [35]. - The company has published 30 peer-reviewed studies demonstrating clinical outcomes, including sustained weight loss and reductions in A1C for members with diabetes [55]. - The company has invested in continuous innovation, including AI-powered tools for meal tracking and nutrition education, enhancing member engagement [48]. - Omada's virtual care model combines human care and technology, enabling personalized, scalable, and cost-effective health experiences [39]. Financial Performance and Risks - The company incurred net losses of $67.5 million, $47.1 million, and $12.8 million for the years ended December 31, 2023, 2024, and 2025, respectively, with an accumulated deficit of $456.7 million as of December 31, 2025 [118]. - The company relies on member engagement and clinical outcomes for revenue, and failure to maintain these could adversely affect financial performance [115]. - A substantial portion of the company's sales comes from a limited number of customers and channel partners, increasing revenue risk [115]. - The company faces significant challenges in managing growth, including recruiting and retaining skilled personnel and maintaining high-quality standards [117]. - Future revenue growth is contingent on attracting new customers and increasing member enrollment, with potential slowdowns if market demand does not meet expectations [147][148]. Regulatory and Compliance Challenges - The company is subject to various federal and state healthcare regulatory laws, including the Anti-Kickback Statute and Stark Law, which impose strict restrictions on business practices in the healthcare industry [83][84][86]. - The Federal False Claims Act prohibits knowingly presenting false claims for payment, with penalties including fines for each false claim and up to three times the damages caused [87]. - The company must navigate complex data privacy laws, including HIPAA and the California Consumer Privacy Act, which impose significant compliance obligations [99][100]. - The company is subject to evolving regulatory frameworks for AI, which could impact its ability to use certain technologies and increase compliance costs [182]. Market and Competitive Landscape - The virtual care market is rapidly evolving and competitive, making it challenging to forecast demand for the company's programs [123]. - The company operates in a highly competitive market with numerous digital health competitors, which may exert pricing pressures and affect market share [128]. - The introduction of superior competitive solutions may create market confusion and pressure pricing, adversely affecting sales and growth forecasts [133]. - The company faces challenges in achieving wide acceptance of its programs among various stakeholders, including employers and health plans, which could hinder growth [124]. Operational and Growth Challenges - The company faces significant risks from natural disasters and catastrophic events, which could materially affect its business operations and financial condition [172]. - The company relies on third-party data centers and hosting providers, including AWS, and any disruptions could harm its ability to deliver programs and negatively impact financial performance [160]. - The company incurs significant upfront costs to establish relationships with customers and channel partners, which may not be recoverable if member engagement is not maintained [141]. - The company faces challenges in managing growth and attracting talent, which could adversely impact its business and financial condition [155]. Technology and Cybersecurity - The company is investing significantly in AI technologies to enhance operational efficiency and member-facing features, including tools like OmadaSpark and Meal Map [176]. - Cybersecurity risks pose a threat to the confidentiality and integrity of the company's IT systems, potentially leading to significant financial liabilities and reputational damage [209]. - The company has experienced cybersecurity incidents, such as the Change Healthcare cyberattack, which, while not materially affecting operations, highlight vulnerabilities in third-party systems [211]. - The proprietary technology may not operate properly, potentially harming the company's reputation and financial condition [214]. Intellectual Property and Brand Management - The company's success depends on maintaining and enforcing intellectual property rights, which if compromised, could harm competitive position [218]. - The patent positions may involve complex legal questions, and the scope of protection cannot be guaranteed [219]. - Trademark protection is essential for brand recognition; challenges to trademarks could lead to rebranding and loss of market identity [224].

Core Insights - Omada Health, Inc. reported revenue of $75.85 million for the quarter ended December 2025, showing no change compared to the same period last year, with an EPS of $0.13 compared to $0 in the year-ago quarter [1] - The revenue exceeded the Zacks Consensus Estimate of $73 million by +3.9%, and the EPS surprised by +420% against the consensus estimate of $0.03 [1] Financial Performance - Total members reached 886,000, surpassing the two-analyst average estimate of 860,009 [4] - Revenue from services was $71.65 million, exceeding the average estimate of $64.53 million by two analysts [4] - Revenue from hardware was $4.2 million, which was below the average estimate of $4.96 million by two analysts [4] Market Position - Over the past month, shares of Omada Health, Inc. returned +0.1%, while the Zacks S&P 500 composite experienced a -0.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - Omada Health achieved 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][30] - The total number of members increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - GAAP net income was $5 million in Q4, marking the first quarter of profitability, and a full-year GAAP net loss of $13 million, an improvement from a loss of $47 million in 2024 [30][35] - Adjusted EBITDA for the full year was $6 million, with a margin of 2%, compared to a loss of $29 million in 2024 [35][36] Business Line Data and Key Metrics Changes - The GLP-1 Care Track program saw significant adoption, with over 150,000 members supported on GLP-1s, contributing to the overall growth in the cardiometabolic suite [10][19] - Revenue from the weight health program grew more than 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][68] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million eligible lives [18] - The total addressable market for Omada is estimated at over $138 billion, with current penetration below 10% [19] Company Strategy and Development Direction - Omada's strategy focuses on innovation, effective programs, and a multi-condition platform to address cardiometabolic health [20][25] - The company plans to expand capabilities in GLP-1 prescribing, cholesterol management, and flexible care options to enhance its service offerings [12][24] - Investments in AI are aimed at improving member support and operational efficiency, with a focus on leveraging unique data sets for personalized care [14][65] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a clear plan for growth, emphasizing the importance of addressing chronic care solutions [4][10] - The healthcare system's inability to scale effectively without a different care model was highlighted, with Omada positioned to fill this gap [8][9] - The company anticipates continued strong growth driven by the demand for multi-condition care and effective enrollment strategies [30][38] Other Important Information - Omada's gross margins expanded significantly, with Q4 GAAP gross margin reaching 71%, up from 67% in the prior year [31] - The company generated positive operating cash flow for the full year and ended 2025 with $222 million in cash and cash equivalents [37] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business contributions without assuming significant improvements in enrollment or engagement metrics [42][44] Question: What are the mechanics of the new GLP-1 Flex Care program? - The GLP-1 Flex Care program is designed to support employers who do not currently cover GLP-1s, providing a structured model for clinical evaluation and prescribing while allowing employees to purchase medications out-of-pocket [54][56] Question: How is Omada leveraging AI in its operations? - Omada is utilizing AI for coding assistance, member support, and enhancing the overall member experience, which is expected to improve margins [64][65] Question: What traction is being seen in the hypertension and diabetes programs? - Growth in diabetes and hypertension programs is strong, with both seeing year-over-year growth rates of 45% or more, reflecting the integrated approach to cardiometabolic care [66][68]

Financial Data and Key Metrics Changes - Omada Health achieved 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][30] - The total member count increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - GAAP net income was positive for the first time in Q4 at $5 million, improving from a net loss of $8 million in Q4 2024 [30][35] - Adjusted EBITDA for the full year was $6 million, a significant improvement from a loss of $29 million in 2024 [30][35] Business Line Data and Key Metrics Changes - Revenue from the weight health program grew over 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][68] - The GLP-1 Care Track saw significant adoption, with over 150,000 members supported on GLP-1s, adding more than 100,000 in 2025 [10][19] - The introduction of the GLP-1 prescribing capability and the new GLP-1 Flexcare option are expected to enhance the company's service offerings and revenue potential [11][22] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million eligible lives [18] - The total addressable market for Omada's services is estimated at over $138 billion, with current penetration below 10% [19] - Government initiatives, such as the PREVENT DIABETES Act, are expected to enhance the recognition of virtual care solutions, expanding access to quality care [19][20] Company Strategy and Development Direction - Omada's strategy focuses on innovation, effective programs, and a multi-condition platform to address cardiometabolic health [20][25] - The company aims to balance growth and profitability, targeting long-term adjusted EBITDA margins of over 20% [16][34] - Investments in AI and technology are expected to enhance member experience and operational efficiency [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a clear plan for growth, driven by market demand for chronic care solutions [4][5] - The company anticipates continued strong performance, with 2026 revenue guidance in the range of $312 million to $322 million, reflecting 22% growth over 2025 [37][38] - Management highlighted the importance of leveraging unique data sets and AI to improve care personalization and operational efficiency [65] Other Important Information - Omada's GAAP gross margin improved to 71% in Q4, up from 67% in the prior year, indicating strong operational leverage [31][32] - The company ended 2025 with $222 million in cash and cash equivalents, having generated positive operating cash flow for the year [37] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business performance without significant contributions from new opportunities, indicating a conservative approach [42][46] Question: How is the GLP-1 FlexCare program structured? - The GLP-1 FlexCare program provides a structured model for employers to support employees with clinical evaluation and prescribing, while allowing employees to purchase medications out-of-pocket [56] Question: What are the growth prospects for diabetes and hypertension programs? - Management noted that growth in diabetes and hypertension programs is strong, with both growing at rates similar to overall revenue growth, reflecting the integrated cardiometabolic approach [66][68]

Financial Data and Key Metrics Changes - Omada Health achieved a 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][29] - The total number of members increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - The company achieved its first quarter of positive GAAP net income in Q4, reporting $5 million, and delivered positive full-year adjusted EBITDA of $6 million [4][34] Business Line Data and Key Metrics Changes - Revenue from the weight health program grew more than 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][69] - The GLP-1 Care Track saw significant adoption, with over 150,000 members supported on GLP-1s, and members on average achieved greater weight loss compared to published real-world evidence [10][11] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million estimated eligible lives [18] - The company noted strong performance across multiple channels, including a successful launch of a large new channel partner [17] Company Strategy and Development Direction - Omada Health is focused on expanding its multi-condition platform, which includes weight health, diabetes, hypertension, and cholesterol management, to provide integrated care solutions [8][24] - The company aims to leverage AI to enhance member support and operational efficiency, embedding AI throughout its services [12][66] - The strategy includes maintaining a balance between growth and profitability, targeting long-term adjusted EBITDA margins of over 20% [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with momentum and a clear plan, highlighting the strong market demand for chronic care solutions and AI-driven innovation [4][5] - The company anticipates 2026 revenue in the range of $312 million to $322 million, reflecting a 22% growth over 2025 [36][37] Other Important Information - Omada Health's GAAP gross margin improved to 71% in Q4, up from 67% in the prior year, and adjusted gross margin reached an all-time high of 73% [30][31] - The company ended 2025 with $222 million in cash and cash equivalents, having generated positive operating cash flow for the year [36] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business contributions and does not include new opportunities like GLP-1 prescribing or FlexCare, which could provide upside [42][46] Question: How did January and February track in terms of conversions? - Management reported strong performance in closing additional eligible covered lives and improved enrollment rates, indicating positive trends early in 2026 [48] Question: What is the impact of the new GLP-1 FlexCare program on economics? - The FlexCare program allows employers to support employees with structured models for GLP-1 access, which includes compensation for Omada for facilitating connections [53][56] Question: How is Omada leveraging AI to improve operations? - Omada is utilizing AI for member support and operational efficiencies, with a focus on unique data sets that enhance personalized care [65][66] Question: What traction is being seen in hypertension and diabetes programs? - Management noted strong growth in both diabetes and hypertension programs, reflecting the integrated cardiometabolic care approach [68][69]

Core Insights - Omada Health has launched GLP-1 Flex Care, a new offering designed to help employers provide access to GLP-1 medications for obesity while managing costs effectively [1][2][3] Group 1: Offering Details - GLP-1 Flex Care connects employees with anti-obesity medication, virtual care, and lifestyle support, allowing members to purchase medications independently through cash-pay channels [1][3] - The program includes clinical evaluation, prescribing, ongoing medical guidance, and oversight, ensuring that employees receive necessary support throughout their GLP-1 journey [3][4] - Members can receive evaluations for GLP-1 eligibility, lab orders, and prescriptions for FDA-approved medications, along with ongoing clinical oversight and lifestyle counseling [3][4] Group 2: Market Demand and Challenges - There is a growing demand for GLP-1 medications among employees, but many employers find full coverage economically challenging [2][4] - Employers are seeking financially sustainable ways to manage GLP-1 coverage while ensuring employees have access to effective treatment options [2][5] - Fragmented cash-pay channels currently lack coordinated medical oversight, leading to concerns about clinical best practices and sustainable outcomes [2][5] Group 3: Effectiveness and Outcomes - Omada's GLP-1 care track has shown strong real-world results, with 67% of members persisting on medication after one year, compared to 47-49% in comparable studies [4] - Members who continued their GLP-1 medication achieved an average weight loss of 18.4% after one year, significantly higher than the 11.9% seen in similar real-world evidence [4][5] - Research indicates that pairing GLP-1 medication with Omada's wraparound care model leads to longer medication adherence and better weight loss outcomes [5] Group 4: Employer Engagement - GLP-1 Flex Care is designed to support diverse employer benefit strategies, catering to various coverage approaches for GLP-1 medications [5][6] - Omada has already supported over 150,000 members on GLP-1s, indicating a strong market presence and commitment to flexible, evidence-based solutions [5][8] - The offering will be available to employers starting later in 2026, providing a timely option for those looking to enhance their employee health benefits [7]

Core Insights - Omada Health, Inc. reported a significant revenue increase of 58% in the fourth quarter and 53% for the full year 2025, reaching $76 million and $260 million respectively [1][7] - The company achieved positive net income of $5 million in the fourth quarter, a notable improvement from a net loss of $8 million in the same quarter of 2024, and narrowed its full-year net loss to $13 million from $47 million in 2024 [8][7] - Omada delivered positive adjusted EBITDA of $8 million in the fourth quarter and $6 million for the full year, compared to adjusted EBITDA losses in the previous year [14][8] Member Growth - Total membership reached 886,000 by year-end 2025, reflecting a 55% year-over-year growth [3] Revenue and Financial Performance - Revenue for the fourth quarter was $76 million, up 58% year-over-year, while the full-year revenue was $260 million, up 53% compared to 2024 [7] - Gross margin improved to 71% in the fourth quarter from 67% in Q4 2024, and for the full year, it was 66%, up from 61% in 2024 [8] - Non-GAAP gross margin for the fourth quarter was 73%, up from 69% in Q4 2024, and for the full year, it was 68%, compared to 63% in 2024 [8] Program Innovations and Offerings - The company introduced GLP-1 Flex Care, a new option for employers to connect eligible employees with clinical evaluation and ongoing medical oversight for GLP-1s, enhancing access and affordability [7][5] - Omada launched AI-powered tools, OmadaSpark and Meal Map, to support members with wellness education alongside human coaches [7][5] - In February 2026, Omada announced a new program, Omada for Cholesterol, to address prevalent conditions often co-existing with diabetes and obesity, expanding its cardiometabolic care capabilities [7][5] Financial Outlook - For the year ending December 31, 2026, Omada expects revenue in the range of $312 million to $322 million, representing a midpoint growth of 22% compared to 2025 [15] - Adjusted EBITDA is projected to be between $7 million and $15 million [15]

Financial Results - Omada Health, Inc. announced preliminary unaudited revenue for Q4 and fiscal year 2025, with results subject to final audit adjustments[5]. - The press release detailing the financial results is attached as Exhibit 99.1 to the Current Report on Form 8-K[5]. Events - The company is participating in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California[5].

Building a Between-Visit Provider As of March 5, 2026 Christine Real Omada Member Important Notice and Disclaimers Disclaimers Our Mission Bend the curve 3 3 This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "tar ...